Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
RVMD
Revolution Medicines Inc.
$39.40
Chart
$36.56 (+7.77%)
$39.21 (+0.48%)
$41.14 (-4.23%)
$38.62 (+2.02%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
RVMD
Revolution Medicines Inc.
Current Price
$39.40
Login to view Revolution Medicines Inc. (RVMD) recommendation from the last 90 days from financial news and social media.
Chart
$36.56 (+7.77%)
$39.21 (+0.48%)
$41.14 (-4.23%)
$38.62 (+2.02%)
RVMD Latest Headlines
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer. REDWOOD CITY Calif. May 14 2025 (GLOBE NEWSWIRE) -- Revolution Medicines Inc. (Nasdaq: RVMD) a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers today announced the first patient has been dosed in RASolve 301 a global randomized open-label Phase 3 clinical trial. RASo
Wed May 14, 2025
Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150 Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight. Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150 Pharma Companies Rigorously Develop Drugs for Market Entry |. DelveInsightMetastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge with low 5-year survival rates and limited durable responses to existing therapies. While standard chemotherapy a
Tue May 13, 2025
Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150 Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight. Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150 Pharma Companies Rigorously Develop Drugs for Market Entry |. DelveInsightMetastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge with low 5-year survival rates and limited durable responses to existing therapies. While standard chemotherapy a
Tue May 13, 2025
Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150 Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight. Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150 Pharma Companies Rigorously Develop Drugs for Market Entry |. DelveInsightMetastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge with low 5-year survival rates and limited durable responses to existing therapies. While standard chemotherapy a
Tue May 13, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
RVMD Stock trends
RVMD Stock performance
RVMD Stock analysis
RVMD investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
